In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
HOME > BUSINESS
BUSINESS
- Novartis Has High Hopes for T-Cell Therapy CTL019
June 10, 2015
- Novartis Japan Chief Vows All-Out Effort to Regain Trust
June 10, 2015
- No Difference from Clinical Trials in Incidence of Adverse Reactions to SGLT-2 Inhibitor: Prof. Kaku of Kawasaki Medical School
June 10, 2015
- R-Tech Ueno Partners with Autonomous University of Barcelona in Research for Development of VAP-1 Inhibitor
June 10, 2015
- Highlights of FY2014 Earnings - Part 5: Lackluster 1% Sales Growth Likely in FY2015
June 10, 2015
- Ethical Drug Sales Up 6.9% in April: Crecon Report
June 9, 2015
- Nesina Similar to Placebo in CV Event Risk in Patients on ACE Inhibitors: Takeda
June 9, 2015
- Once-Weekly Omarigliptin Reduces HbA1c Levels as Add-on Treatment in PIII Study in Japanese Patents: MSD
June 9, 2015
- Highlights of FY2014 Earnings - Part 4: Overseas Sales Top 4 Trillion Yen; Fate of Drug Makers Will Depend on New Global Products
June 9, 2015
- Highlights of FY2014 Earnings - Part 3: New Cancer Drugs Off to Strong Start
June 8, 2015
- Lilly Hopes Alzheimer’s Drug Solanezumab Will Be World’s First-in-Class
June 5, 2015
- Japan Should Open Up AMED’s Achievements Globally: Lilly Execs
June 5, 2015
- Lilly Japan Plans Excursion to Local Cities in Quest for Novel Drug Seeds
June 5, 2015
- No. of Hospitals with Less than 20% Generic Prescription Rate Down Sharply: Survey
June 5, 2015
- Highlights of FY2014 Earnings - Part 2: Sales of 42 Major Long-Listed Products Sag Nearly 20%
June 5, 2015
- Aspen Japan Commences Operations in Japan
June 5, 2015
- Takecab Ranks 1st for 4th Month Running in GP, HP Markets in April: Anterio Ranking
June 4, 2015
- Takeda to Set Up Global Vaccine Business Hub in US
June 4, 2015
- Highlights of FY2014 Earnings - Part 1: 35 Listed Drug Makers See Downtrend in Profits Despite 3% Sales Uptick
June 4, 2015
- MSD Transfers Marketing Rights for Claritin to Bayer Yakuhin
June 3, 2015
ページ
The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
Will an “off-year” drug price revision happen in April 2025 or not? Over the last week, expectations have been up…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…